Luminex announced that it has launched its pharmacogenetic test, the xTAG CYP2D6 Kit, which is approved by the FDA to help identify individuals who possess both common and rare CYP2D6 poor-metabolizer variants. CYP2D6 is an enzyme that is involved in the metabolism of approximately one quarter of all prescription drugs, including β-blockers, opiates, selective serotonin reuptake inhibitors (SSRIs), tricylic antidepressants (TCAs), neuroleptics and antiarrhythmics. People may carry a slow- or fast–acting form of the enzyme while others have a non-functional version of the CYP2D6 gene, or allele, which can affect how an individual’s body responds to these therapies.
The xTAG CYP2D6 Kit is a qualitative genotyping assay that can simultaneously detect and identify a panel of single-nucleotide polymorphism (SNP) variants found within the CYP2D6 gene. It also identifies gene rearrangements associated with deletion and duplication genotypes. Results can be provided in eight hours.
For more information call (512) 219-8020 or visit www.luminexcorp.com.